Prelude Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Prelude Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-48,414	Closed	-$83.3K	–	1145
2024 Q4	$83.3K	Sell	48,414 -4,003	-8%	-$9.64K	0.01%	1111
2024 Q3	$130K	Buy	52,417 +6,007	+13%	+$16.3K	0.01%	1129
2024 Q2	$112K	Buy	46,410 +9,410	+25%	+$30K	0.01%	1087
2024 Q1	$150K	Buy	37,000 +7,900	+27%	+$29.8K	0.01%	1163
2023 Q4	$112K	Buy	+29,100	New	+$86.4K	0.01%	1018
2023 Q3	–	Sell	-31,100	Closed	-$150K	–	1109
2023 Q2	$150K	Buy	+31,100	New	+$149K	0.01%	882
2022 Q3	–	Sell	-18,500	Closed	-$87K	–	1545
2022 Q2	$87K	Buy	18,500 +2,900	+19%	+$10.9K	﹤0.01%	1434
2022 Q1	$61K	Buy	+15,600	New	+$84.9K	﹤0.01%	1475

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Prelude Capital Management's ABOS Position: Q1 2025 in Review

Prelude Capital Management sold out of Acumen Pharmaceuticals (ABOS) in Q1 2025, closing a stake of 48,414 shares — an estimated $83.3K sold.

Prelude Capital Management first reported a position in ABOS in Q1 2022 and held it in 8 quarters. The position peaked at $150K in Q1 2024. 81 funds tracked by Wall St. Rank hold ABOS as of Q1 2025.

Prelude Capital Management reported no remaining Acumen Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Prelude Capital Management sold 48,414 Acumen Pharmaceuticals shares in Q1 2025, an estimated $83.3K.
Prelude Capital Management first reported a position in Acumen Pharmaceuticals in Q1 2022 and held it in 8 quarters.
Prelude Capital Management's Acumen Pharmaceuticals position peaked at $150K in Q1 2024.
81 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.